Mylan
1000 Mylan Boulevard
Canonsburg
Pennsylvania
15317
United States
Tel: 724-514-1800
Website: http://www.mylan.com/
About Mylan
Mylan is a global pharmaceutical company committed to setting new standards in healthcare. Working together around the world to provide 7 billion people access to high quality medicine, Mylan innovates to satisfy unmet needs; make reliability and service excellence a habit; do what's right, not what's easy; and impact the future through passionate global leadership
YEAR FOUNDED:
1961
LEADERSHIP:
Founders: Milan Puskar, and Don Panoz
CEO: Heather Bresch
CFO: Neil Dimick
PRODUCTS:
All Products
897 articles with Mylan
-
The Food and Drug Administration is taking care of a few approvals and committee meetings ahead of the Thanksgiving holiday week. They include drugs for COPD, a pain drug, and a sublingual film formulation of a well-known drug for erectile dysfunction. Here’s a look.
-
Theravance Biopharma and Mylan Receive FDA Approval for YUPELRI™ (revefenacin) in Adults with Chronic Obstructive Pulmonary Disease
11/9/2018
YUPELRI (revefenacin) is the first and only once-daily, nebulized bronchodilator approved for the treatment of COPD in the US
-
Allergan indicated that it “has shifted [its] priority from expanding the Waco site to investing significantly in our existing operations.” However, the company spokesperson said that Allergan “remains committed to our eye care business and operations in Waco.”
-
Mylan Reports Third Quarter 2018 Results and Reaffirms 2018 Guidance
11/5/2018
Mylan N.V. (NASDAQ: MYL) today announced its financial results for the quarter and nine months ended September 30, 2018.
-
Biopharma companies set to release financial reports next week have reported positive news in recent months.
-
The U.S. Food and Drug Administration (FDA) gave the green light to Hyrimoz, a biosimilar to AbbVie’s blockbuster drug Humira, five years ahead of the time it can be launched in U.S. markets.
-
Mylan and Biocon Announce Positive CHMP Opinion for Ogivri®, Biosimilar Trastuzumab
10/19/2018
Mylan N.V. and Biocon Ltd. today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending approval of Ogivri®, a biosimilar to Roche's Herceptin® (trastuzumab).
-
Mylan Launches Hulio™ (Biosimilar Adalimumab) in Markets Across Europe
10/19/2018
Global pharmaceutical company Mylan N.V. (NASDAQ: MYL) today announced that it has initiated the commercial launch of Hulio™, a biosimilar to AbbVie's Humira® (adalimumab), across major markets in Europe.
-
Part of the Trump Administration and the U.S. Food and Drug Administration (FDA)’s strategy to push down drug prices is to develop ways to increase competition. As such, the agency launched a Drug Competition Action Plan that has several components.
-
19 (at Least!) of TIME Magazine’s 50 Most Influential Healthcare People Have Biopharma Ties
10/19/2018
TIME Magazine came out with a list of the 50 most influential people in healthcare, dubbed The Health Care 50. A look through the list shows just how many ties and connections—as well as influence—this group has on the biopharma industry. -
Mylan to Release Third Quarter 2018 Financial Results on November 5, 2018
10/18/2018
The company also will host a webcast at 5:00 p.m. ET on Nov. 5, to discuss the results.
-
AbbVie’s Humira is the world’s best-selling drug that generated more than $18 billion for the Illinois-based company last year. This week though, the company will begin to see challenges to Humira in Europe from biosimilars developed by Amgen and Novartis, as well as others.
-
Mylan Prevails in Copaxone® 40mg/mL Litigation Against Teva in U.S. Appellate Court
10/12/2018
Mylan N.V. (NASDAQ: MYL) today announced that the United States Court of Appeals for the Federal Circuit has affirmed the District of Delaware's decision that Teva's Copaxone® 40 mg/mL dosing patents are invalid as obvious
-
Theravance Biopharma and Mylan Report Positive New Data from Multiple Studies of YUPELRI™ (revefenacin) at the 2018 CHEST Annual Meeting
10/11/2018
Additional Analyses of Phase 3 Program Data Highlight Efficacy Advantages for 175 mcg/day of YUPELRI in Key Patient Subgroups, Demonstrate Acceptable Cardiovascular Safety Profile
-
The AP in a recent report notes that drug price increases “slowed somewhat and were not quite as steep as in past years.” But overall, there has been no “massive” drug price cuts.
-
Theravance Biopharma and Mylan to Present New Data from Studies of YUPELRI™ (revefenacin) at the 2018 CHEST Annual Meeting
10/8/2018
Presentations Highlight Data of YUPELRI Compared with Tiotropium in Subpopulation of COPD Patients with Suboptimal Peak Inspiratory Flow Rates, Report Additional Data from Pivotal Phase 3 Program in Patients with Moderate to Very Severe COPD
-
Despite winning regulatory approval for a copycat version of Copaxone earlier this year, Cambridge, Mass.-based Momenta Pharmaceuticals has completed a strategic review that includes slashing its staff by 50 percent as the company focuses its resources on two biosimilar candidates in its pipeline.
-
Mylan Extends Commitment to Fight HIV/AIDS by Partnering with Atomo Diagnostics to Expand Access to HIV Self-Testing in Low- and Middle-Income Countries
9/24/2018
Mylan N.V. and medical device company Atomo Diagnostics today announced a strategic partnership to commercialize CE-Marked in vitro HIV rapid diagnostic tests for self-testing in low- and middle-income countries.
-
Mylan and Fujifilm Kyowa Kirin Biologics Receive European Marketing Authorization for Hulio®, Biosimilar Adalimumab
9/20/2018
Mylan N.V. and Fujifilm Kyowa Kirin Biologics Co., Ltd. today announced that the European Commission (EC) has granted marketing authorization for Hulio® (Product Code: FKB327), a biosimilar to AbbVie's Humira® (adalimumab), for all indications.
-
Theravance Biopharma and Mylan Report New Data from Phase 3 Studies of YUPELRI™ (revefenacin) in Oral Presentation at the European Respiratory Society International Congress
9/17/2018
Reduction in Rates of COPD Exacerbations Observed in COPD Patients Treated with YUPELRITM Compared to Placebo and Tiotropium (Spiriva® HandiHaler®)